FDA approves Dizal's EGFR inhibitor Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 3 July, 2025

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

spotlight In Focus China’s rise splits US biotech investors: Cash in, or counter?

news Sage talked to 43 'counterparties' before inking Supernus deal 4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plans Dizal’s lung cancer pill approval sets up competition with J&J Exclusive: German CDMO BioSpring embarks on €100M+ nucleic acid factory Peer Review Now private, bluebird bio continues leadership revamp; Roche R&D exec announces retirement

Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trials sponsored by Precision for Medicine Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Post-Hoc Live is now available to stream. Catch full episodes on YouTube or listen on Spotify and Apple Podcasts. Be sure to subscribe so you don’t miss what’s next.

endpoints pharma FDA reviewers advised broad label for Moderna’s next-gen Covid vaccine. Prasad overruled them Bristol Myers' China partner touts Phase 3 success for EGFRxHER3 bispecific ADC CDC expands RSV vaccine recommendations, siding with previous panel of agency advisors AbbVie loses bid to block Tennessee's 340B contract pharmacy law

in case you missed it 1. AbbVie cans oral ulcerative colitis drug from Landos buyout 2. After delay, Regeneron wins US approval of bispecific in multiple myeloma 3. Soriot mulls moving AstraZeneca stock listing to the US — report 4. Shionogi, BioVersys team up on antibiotics for lung disease in deal worth up to $614M 5. Vyne stops enrolling early-stage psoriasis study following clinical hold lift, early data 6. London’s New Listings Hit 28-Year Low as AstraZeneca Weighs Exit